パーキンソン病患者におけるIPS101Aの安全性、有効性、および薬物動態を評価する第1相臨床試験
用量漸増、単一施設、オープンラベル第1相臨床試験:ホーエン・ヤール重症度分類ステージ4-5、診断後10年以上経過し、すべての利用可能な単剤療法または併用療法でコントロール不良のパーキンソン病患者におけるアデノ随伴ウイルス(AAV)遺伝子治療製品IPS101Aの安全性、有効性、および薬物動態を評価する
The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:ChoLong Park
- 電話番号:+82-2-3499-4266
- メール:clpark@innopeutics.com
研究連絡先のバックアップ
- 名前:Tae-gyun Kim
- メール:contact@innopeutics.com
研究場所
-
-
-
Seoul、韓国
- 募集
- Severance Hospital
-
コンタクト:
- Professor, MD, PhD
- メール:phlee@yuhs.ac
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
- Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
- Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
- Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
- Subjects with a Hoehn & Yahr stage of 4 or 5 in the off state at the Screening Visit.
Exclusion Criteria:
- Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
- Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
- Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
- Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
- Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
- Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Low dose (1.0 x 10^10 vg/patient)
IPS101A |
The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side. |
|
実験的:High dose(2.0 x 10^10 vg/patient)
IPS101A |
The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety Evaluation: dose-limiting toxicity (DLT)
時間枠:Baseline to Week 8
|
Frequency and proportion of subjects who developed dose-limiting toxicity (DLT) |
Baseline to Week 8
|
|
Safety Evaluation: Severity and frequency of reported adverse events
時間枠:Baseline to Week 52
|
Assess severity and frequency of reported adverse events |
Baseline to Week 52
|
|
Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel
時間枠:Baseline to Week 52
|
The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration. |
Baseline to Week 52
|
|
Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel
時間枠:Baseline to Week 52
|
The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur. |
Baseline to Week 52
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
時間枠:Baseline to Weeks 4, 12, 24, 36, and 52.
|
Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease. |
Baseline to Weeks 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Hoehn & Yahr stage (defined on/off)
時間枠:Weeks 1, 4, 12, 24, 36, and 52.
|
This scale is classified from 0 to 5, with a higher score indicating a more severe degree of Parkinson's disease. |
Weeks 1, 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Non-Motor Symptoms Scale for Parkinson's Disease (NMSS)
時間枠:Weeks 4, 12, 24, 36, and 52.
|
This scale is rated on a scale of severity (0-3 points) and frequency (1-4 points). A higher score indicates more severe Parkinson's disease. |
Weeks 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) scores
時間枠:Weeks 4, 12, 24, 36, and 52
|
The scale consists of 800 points, and a higher score indicates a lower quality of life. |
Weeks 4, 12, 24, 36, and 52
|
|
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-CSF
時間枠:Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
|
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-blood
時間枠:Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
|
Evaluation of humoral (anti-AAV9 antibodies) and cellular (IFN-γ activity) immune responses to AAV9
時間枠:Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using ELISA |
Baseline to Week 52
|
|
Assessment of AAV9 shedding in biological specimens-urine
時間枠:Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。